Drug intelligence / Profile preview

cefpodoxime + ciprofloxacin

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral, Intravenous, Ophthalmic, Otic

Overview

This is a combination of two antibiotics: cefpodoxime, a third-generation cephalosporin, and ciprofloxacin, a second-generation fluoroquinolone. Both medications are used to treat various bacterial infections, though they work through different mechanisms of action. Cefpodoxime kills bacteria by preventing them from making protective cell walls, while ciprofloxacin inhibits bacterial DNA replication. This combination is not a standard fixed-dose combination product but may be prescribed together in specific clinical situations.

Targets

Topo IV (Bacterial Topoisomerase IV)PBP (Penicillin-binding protein family)DNA gyrase

Beyond the preview

Go deeper on cefpodoxime + ciprofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefpodoxime + ciprofloxacin.

Explore the full profile